Impact of IL-12 and IL-18 Combined Stimulation on INF-γ and TNF-α Production by PBMCs Derived from Egyptian Ovarian Cancer Patients

Background: Cytokines play a crucial role in modulating the immune cells' response to tumors. Utilizing IL-18 and IL-12 as immunotherapeutic agents has gained much attention for cancer treatment. This study aimed to investigate the effect of combined stimulation with IL-12 and IL-18 on the abil...

Full description

Saved in:
Bibliographic Details
Published in:International journal of biomedicine Vol. 14; no. 3; pp. 435 - 400
Main Authors: Nourhan E. Mohamed, Noha A. Mahana, Abeer Mahmoud Badr, Ola S. Ahmed, Ahmed M. Lymona, Sarah S. Nasr
Format: Journal Article
Language:English
Published: International Medical Research and Development Corporation 01-09-2024
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Cytokines play a crucial role in modulating the immune cells' response to tumors. Utilizing IL-18 and IL-12 as immunotherapeutic agents has gained much attention for cancer treatment. This study aimed to investigate the effect of combined stimulation with IL-12 and IL-18 on the ability of peripheral blood mononuclear cells (PBMCs) derived from Egyptian ovarian cancer (OC) patients to produce IFN-γ and TNF-α. Methods and Results: This in vitro study included 8 patients with benign ovarian tumors, 8 patients with low-grade OC, and 8 patients with high-grade OC. PBMCs were stimulated with IL-12 (10ng/ml) and IL-18 (50ng/ml) for 7 days. The levels of IFN-γ and TNF-α were quantified before and after stimulation by quantitative sandwich ELISA. Stimulated PBMCs isolated from patients with low-grade OC showed good ability to produce high levels of IFN-γ, while stimulated PBMCs isolated from patients with high-grade OC patients showed good and high production of TNF-α. Conclusion: We found that the combined stimulation with IL-12 and IL-18 significantly enhances the production of IFN-γ and TNF-α by PBMCs in OC patients, suggesting a potential avenue for cancer immunotherapy.
ISSN:2158-0510
2158-0529
DOI:10.21103/Article14(3)_OA7